What’s new

• FY26 revenue dropped to ₹2,373.16 lacs from ₹4,331.19 lacs a year ago.
• Net loss improved to ₹1,693.31 lacs from ₹2,692.40 lacs.
• Vizag plant remains shut since Feb 2025 pollution board order.

Why it matters

Krebs' only manufacturing plant has been shut for over a year, halving revenue. The marginal loss reduction is insufficient to offset the cash burn. With net worth at negative ₹16,275.47 lacs, the company's viability hinges on restarting the Vizag unit—a scenario with no public timeline.

What we’re watching

• Any update on Vizag plant compliance or restart.
• Debt restructuring or equity infusion plans.
• Q1 FY27 performance—whether losses continue to narrow.

The full read

Krebs Biochemicals' FY26 results confirm a company in operational distress. Revenue fell to ₹2,373.16 lacs from ₹4,331.19 lacs as its Vizag plant remained closed since February 2025 following a pollution board order. Net loss narrowed to ₹1,693.31 lacs from ₹2,692.40 lacs, but the improvement is marginal when set against the revenue collapse and net worth that deepened to negative ₹16,275.47 lacs. This is a routine filing with no surprises—the market had already priced in the plant closure. The open question is whether the company can ever restart operations or if this marks a slow unwinding.

Primary source: BSE · NSE